In silico screening for clinical efficacy of antiseizure medications: Not all central nervous system drugs are alike
Open Access
Abstract
No abstract availableKeywords
Funding Information
- Israel Science Foundation (2054/18)
- Hebrew University of Jerusalem
This publication has 57 references indexed in Scilit:
- Consequences of Repeated Blood-Brain Barrier Disruption in Football PlayersPLOS ONE, 2013
- Inhibition of mammalian target of rapamycin reduces epileptogenesis and blood–brain barrier leakage but not microglia activationEpilepsia, 2012
- Blood-Brain Barrier Breakdown Following Traumatic Brain Injury: A Possible Role in Posttraumatic EpilepsyCardiovascular Psychiatry and Neurology, 2011
- Evaluation of Focal Cortical Dysplasia and Mixed Neuronal and Glial Tumors in Pediatric Epilepsy Patients Using18F-FDG and11C-Methionine PETJournal of Nuclear Medicine, 2010
- Defining Desirable Central Nervous System Drug Space through the Alignment of Molecular Properties, in Vitro ADME, and Safety AttributesACS Chemical Neuroscience, 2010
- Physiochemical drug properties associated with in vivo toxicological outcomesBioorganic & Medicinal Chemistry Letters, 2008
- Structure−Brain Exposure RelationshipsJournal of Medicinal Chemistry, 2006
- Drug resistance in brain diseases and the role of drug efflux transportersNature Reviews Neuroscience, 2005
- Classification Analysis of P-Glycoprotein Substrate SpecificityJournal of Drug Targeting, 2003
- Non-stokesian nature of transverse diffusion within human red cell membranesThe Journal of Membrane Biology, 1986